Regulation & Compliance

Claire Elyse Brosseau launches an emergency legal bid to access assisted dying for mental illness, challenging Canada's repeated legislative delays.

Valion Bio's new General Counsel, a rare blend of scientist and lawyer, is poised to navigate its radiation drug through the FDA's complex Animal Rule.

Hundreds of teddy bears reveal a stark reality: nearly half of Albertans face sexual violence, and support services are overwhelmed. Can a new campaign help?

A landmark deal brings a promising, but unapproved, therapy for a rare blinding disease to French patients via a special compassionate use program.

Prismm joins Jack Henry's network to help banks retain assets as unprecedented generational wealth transfer looms, threatening massive deposit flight.

Angela Kurkian, a veteran photographer, takes the helm at PPA, succeeding David Trust and setting a course to guide members through a changing industry.

Morningstar's investment chief joins a health AI firm, signaling a new era where financial modeling principles could unlock preventative wellness for millions.

A new report reveals Canada's Intelligence Commissioner is pushing back on spy agencies, protecting rights and democratic institutions like never before.

With a decade of international experience, Knighthead Life launches its Chartline annuities, promising transparency in a booming U.S. retirement market.

A German biotech's novel in vivo CAR T platform uses DNA for durable tumor control, aiming to make advanced cancer therapy an off-the-shelf medicine.

The HLAA 2026 convention showcases AI breakthroughs, policy debates, and the power of community for 50 million Americans with hearing loss.

The clinical-stage biotech adds seasoned veterans from Eli Lilly and Iovance to accelerate its promising DNA Damage Response pipeline toward commercialization.

Valitor's VLTR-559 shows superior durability in preclinical data, potentially slashing wet AMD treatment from monthly injections to just two per year.

Veteran marketing leader Sandhya G. Davis joins the self-regulation body, a strategic move to bolster consumer trust amid AI and data privacy challenges.

Athene targets the booming RILA market with Amplify 3.0, a new annuity focused on simplification, user control, and expanded downside protection options.

With backing from Eli Lilly, Cabaletta Bio's $150M financing will accelerate its potentially curative cell therapies for autoimmune diseases.

GRIN Therapeutics expands its pivotal Phase 3 study for radiprodil to Europe, fueling hope for a first-ever targeted therapy for a rare neurological disorder.

This week's Alert Ready test is more than a drill. It reveals a system's successes, its regional divides, and the private firm at its core.

Spanish CDMO ROIS acquires a major Phoenix facility from Bristol Myers Squibb, securing US drug supply chains and expanding its global footprint.

Ncontracts' new Nquiry platform combines 17 years of data with human experts, promising financial firms fast, defensible answers in a complex regulatory world.